October 2025
-
Press release
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trialsNEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary…
-
Press release
Novartis completes acquisition of Tourmaline BioBasel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common…
-
Press release
Novartis announces expiration of Tourmaline Bio tender offerBasel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned…
-
Ad hoc release
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidanceAd hoc announcement pursuant to Art. 53 LRQ3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority…
-
Ad hoc release
Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigtAd-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +7% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +7% (kWk, +6% USD)Das Umsatzwachstum beruhte…
-
Ad hoc release
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipelineAd hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the…
-
Press release
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseasesLate-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell therapy…
-
Press release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo…
-
Press release
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offerBasel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection…
-
Press release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancerPluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-…
-
Press release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient populationAfter 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor…